Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies

Objective To estimate the probabilistic cost-effectiveness of cascade screening methods in familial hypercholesterolaemia (FH) from the UK NHS perspective. Design Economic evaluation (cost utility analysis) comparing four cascade screening strategies for FH: Using low-density lipoprotein (LDL) cholesterol measurements to diagnose affected relatives (cholesterol method); cascading only in patients with a causative mutation identified and using DNA tests to diagnose relatives (DNA method); DNA testing combined with LDL-cholesterol testing in families with no mutation identified, only in patients with clinically defined ‘definite’ FH (DNA+DFH method); DNA testing combined with LDL-cholesterol testing in no-mutation families of both ‘definite’ and ‘probable’ FH patients (DNA+DFH+PFH). A probabilistic model was constructed to estimate the treatment benefit from statins, with all diagnosed individuals receiving high-intensity statin treatment. Population A cohort of 1000 people suspected of having FH aged 50 years for index cases and 30 years for relatives, followed for a lifetime. Main outcomes Costs, quality-adjusted life-years (QALY) and incremental cost-effectiveness ratios (ICER). Results The DNA+DFH+PFH method was the most cost-effective cascade screening strategy. The ICER was estimated at £3666/QALY. Using this strategy, of the tested relatives 30.6% will be true positives, 6.3% false positives, 61.9% true negatives and 1.1% false negatives. Probabilistic sensitivity analysis showed that this approach is 100% cost-effective using the conventional benchmark for cost-effective treatments in the NHS of between £20 000 and £30 000 per QALY gained. Conclusion Cascade testing of relatives of patients with DFH and PFH is cost-effective when using a combination of DNA testing for known family mutations and LDL-cholesterol levels in the remaining families. The approach is more cost-effective than current primary prevention screening strategies.

[1]  C. Boileau,et al.  Genetic heterogeneity of autosomal dominant hypercholesterolemia , 2007, Clinical genetics.

[2]  S. Humphries,et al.  Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing , 2008, Clinical chemistry and laboratory medicine.

[3]  S. G. Hadfield,et al.  Family tracing to identify patients with Familial Hypercholesterolaemia: the second Audit of the Department of Health Familial Hypercholesterolaemia Cascade Testing Project , 2009, Annals of clinical biochemistry.

[4]  R. Levy,et al.  Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. , 1974, The Journal of clinical investigation.

[5]  J. Robson,et al.  Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease , 2007, Heart.

[6]  Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. , 1991, BMJ.

[7]  Carolyn M Hutter,et al.  Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. , 2004, American journal of epidemiology.

[8]  S. Humphries,et al.  Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study , 2008, European heart journal.

[9]  S. Humphries,et al.  Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia , 2010, Current medical research and opinion.

[10]  S. Humphries,et al.  Comparing costs and benefits over a 10 year period of strategies for familial hypercholesterolaemia screening. , 2003, Journal of public health medicine.

[11]  Andrew Briggs,et al.  Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions. , 2004, Health economics.

[12]  I. Young,et al.  Genetic screening protocol for familial hypercholesterolemia which includes splicing defects gives an improved mutation detection rate. , 2005, Atherosclerosis.

[13]  R. H. Dalaqua.  University College, London , 1910, Nature.

[14]  Carol Coupland,et al.  Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database , 2010, BMJ : British Medical Journal.

[15]  Carol Coupland,et al.  Individualising the risks of statins in men and women in England and Wales: population-based cohort study , 2010, Heart.

[16]  S. Humphries,et al.  Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk , 2006, Journal of Medical Genetics.

[17]  S. Humphries,et al.  Familial hypercholesterolaemia: summary of NICE guidance , 2008, BMJ : British Medical Journal.

[18]  S. Humphries,et al.  A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. , 2003, Atherosclerosis.

[19]  M. Pfeffer,et al.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.

[20]  O. Faergeman,et al.  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.

[21]  L. Curtis,et al.  Unit Costs of Health and Social Care 2016 , 2015 .

[22]  S. G. Hadfield,et al.  Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project , 2010, Clinical genetics.

[23]  A. Dhar,et al.  National Institute for Health and Clinical Excellence , 2005 .

[24]  Disciplinary Committee,et al.  Royal Pharmaceutical Society of Great Britain , 2002 .

[25]  S. Humphries,et al.  Census of clinics providing specialist lipid services in the United Kingdom. , 2004, Journal of public health.

[26]  Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. , 1999, Atherosclerosis.

[27]  Margaret Thorogood,et al.  Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia , 2002, BMJ : British Medical Journal.

[28]  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[29]  S. Humphries,et al.  Risk of Fatal Stroke in Patients With Treated Familial Hypercholesterolemia: A Prospective Registry Study , 2003, Stroke.

[30]  J. Kastelein,et al.  Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands. , 2004, Seminars in vascular medicine.

[31]  References , 1971 .

[32]  A. Whitelaw,et al.  Diagnosing familial hypercholesterolaemia in childhood by measuring serum cholesterol. , 1977, British medical journal.

[33]  Thomas Weber,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[34]  S. Humphries,et al.  Mutation screening in patients for familial hypercholesterolaemia (ADH) , 2010, Clinical genetics.